X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT AUROBINDO PHARMA/
WOCKHARDT
 
P/E (TTM) x 16.9 -21.3 - View Chart
P/BV x 3.3 1.5 222.8% View Chart
Dividend Yield % 0.4 0.0 14,570.2%  

Financials

 AUROBINDO PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
WOCKHARDT
Mar-18
AUROBINDO PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs8091,012 79.9%   
Low Rs504532 94.8%   
Sales per share (Unadj.) Rs281.1355.9 79.0%  
Earnings per share (Unadj.) Rs41.4-60.3 -68.6%  
Cash flow per share (Unadj.) Rs50.9-46.8 -108.8%  
Dividends per share (Unadj.) Rs2.500.01 25,000.0%  
Dividend yield (eoy) %0.40 29,388.8%  
Book value per share (Unadj.) Rs199.4257.8 77.3%  
Shares outstanding (eoy) m585.88110.63 529.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.2 107.7%   
Avg P/E ratio x15.9-12.8 -124.0%  
P/CF ratio (eoy) x12.9-16.5 -78.2%  
Price / Book Value ratio x3.33.0 110.0%  
Dividend payout %6.00 -36,439.0%   
Avg Mkt Cap Rs m384,63085,379 450.5%   
No. of employees `00017.36.3 277.1%   
Total wages/salary Rs m21,3089,371 227.4%   
Avg. sales/employee Rs Th9,500.76,295.0 150.9%   
Avg. wages/employee Rs Th1,229.41,498.3 82.1%   
Avg. net profit/employee Rs Th1,397.9-1,066.3 -131.1%   
INCOME DATA
Net Sales Rs m164,66639,369 418.3%  
Other income Rs m1,0201,202 84.8%   
Total revenues Rs m165,68640,571 408.4%   
Gross profit Rs m37,71818 206,106.6%  
Depreciation Rs m5,5801,495 373.1%   
Interest Rs m7772,555 30.4%   
Profit before tax Rs m32,380-2,830 -1,144.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m8,183257 3,183.9%   
Profit after tax Rs m24,229-6,669 -363.3%  
Gross profit margin %22.90 49,276.8%  
Effective tax rate %25.3-9.1 -278.2%   
Net profit margin %14.7-16.9 -86.9%  
BALANCE SHEET DATA
Current assets Rs m121,87833,796 360.6%   
Current liabilities Rs m86,80626,917 322.5%   
Net working cap to sales %21.317.5 121.9%  
Current ratio x1.41.3 111.8%  
Inventory Days Days13079 163.7%  
Debtors Days Days6889 76.6%  
Net fixed assets Rs m81,03739,664 204.3%   
Share capital Rs m586553 105.9%   
"Free" reserves Rs m116,21827,968 415.5%   
Net worth Rs m116,80428,522 409.5%   
Long term debt Rs m4,51221,731 20.8%   
Total assets Rs m211,05281,620 258.6%  
Interest coverage x42.7-0.1 -39,679.4%   
Debt to equity ratio x00.8 5.1%  
Sales to assets ratio x0.80.5 161.8%   
Return on assets %11.8-5.0 -235.1%  
Return on equity %20.7-23.4 -88.7%  
Return on capital %27.4-7.7 -356.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7279,807 823.2%   
Fx outflow Rs m34,7001,789 1,940.1%   
Net fx Rs m46,0278,019 574.0%   
CASH FLOW
From Operations Rs m19,548684 2,856.3%  
From Investments Rs m-19,5706,302 -310.5%  
From Financial Activity Rs m8,642-7,695 -112.3%  
Net Cashflow Rs m8,922-664 -1,343.7%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PLETHICO PHARMA  BIOCON   FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Hit Record High as Exit Polls Predict NDA Win; Sensex Ends 1,421 Points Higher(Closing)

Indian share markets witnessed huge buying interest today. The benchmark indices opened gap-up after Exit Polls for the Lok Sabha Elections 2019.

Related Views on News

CAPLIN POINT Surges by 5%; BSE HEALTHCARE Index Up 0.8% (Market Updates)

May 20, 2019 | Updated on May 20, 2019

CAPLIN POINT share price has surged by 5% and its current market price is Rs 378. The BSE HEALTHCARE is up by 0.8%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 5.4%) and PIRAMAL ENTERPRISES (up 6.9%). The top losers are GLENMARK PHARMA and BLISS GVS PHARMA (down 0.1%).

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)

May 7, 2019

How a niche tech startup battled all odds to eventually become a 10 bagger.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 20, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS